Large Outflow of Money Witnessed in Corindus Vascular Robotics

Corindus Vascular Robotics (NYSEMKT:CVRS) During the most recent session, the shares traded at 0.13 points or 8.78% higher at $1.61. The money flow data is unimpressive with the net money flow value of $(-0.8) million. As per the intraday data, the upticks measured $0.26 million and the downticks measured $1.06 million. As a result, the up/down ratio registered a value of 0.25. The shares have seen 38.79% price change for the week.A block trade also made an entry with $0.03 million flowing in through upticks while $0.73 million flew out through downticks. The block tradeoff had the up/down ratio of 0.05. The net money flow for this big transaction was $(-0.69) million.


Currently the company Insiders own 39.31% of Corindus Vascular Robotics shares according to the proxy statements. Institutional Investors own 59.9% of Corindus Vascular Robotics shares.

Corindus Vascular Robotics (NYSEMKT:CVRS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.18 points or 11.18% at $1.43 with 279,491 shares getting traded. Post opening the session at $1.69, the shares hit an intraday low of $1.4 and an intraday high of $1.69 and the price was in this range throughout the day. The company has a market cap of $170 million and the number of outstanding shares have been calculated to be 118,934,152 shares. The 52-week high of Corindus Vascular Robotics (NYSEMKT:CVRS) is $4.58 and the 52-week low is $0.731.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Sterne Agee CRT, maintains their rating on the shares of Corindus Vascular Robotics (NYSEMKT:CVRS). Sterne Agee CRT has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $3 per share. The rating by the firm was issued on April 20, 2016.

Corindus Vascular Robotics, Inc. designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Companys product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. It installed 24 CorPath Systems in hospitals in the United States and two CorPath Systems in hospitals outside of the United States. The CorPath System consists of two components: a bedside unit and an interventional cockpit. The CorPath System allows physicians to measure anatomy with sub-millimeter accuracy and manipulate the interventional device in one millimeter increments and with 30-degree rotational movements.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.